 asked Maha H. Hussain, MD: How will the advent of PARP inhibitors change the management of advanced prostate cancer? 

PARP inhibitor significantly extends rPFS vs. hormonal therapy

Focal therapy vs. surveillance for low-risk PCa

Medicare final rule: Changes affect cysto, prostate Bx reimbursement

Stone recurrence: Advice for young urologists

Genitourinary Cancers

Prostate Cancer

Urology Times asked Maha H. Hussain, MD: How will the advent of PARP inhibitors change the management of advanced prostate cancer?